Ori Biotech

Introducing IRO®, the new standard in CGT manufacturing technology. 🎉 Manufacturing remains a critical barrier to scaling cell and gene therapies – making it difficult to meet the patient need, and limiting the clinical and commercial impact of this new class of therapies. That’s why we developed IRO®. IRO® combines an efficient and flexible platform with a scalable, digital solution to industrialize precision medicine manufacturing – delivering a seamless transition from R&D into the clinic, and from clinical scale to commercial scale. By empowering scientists with tools that help accelerate product development and Automate Better Biology, we are working to help enable widespread patient access and scale the impact of life-changing cell and gene therapies. Thank you to everyone who attended our launch at ISCT today. It's an incredibly exciting moment to finally unveil our work over the past 5-years – we are very grateful to the Ori team and our partners for helping us achieve this milestone. Read our full press release: https://lnkd.in/eT3B3MSf Schedule a hands on demo to see how IRO® could work for you: https://lnkd.in/eXEXEGZZ #ISCT2024 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #Biotechnology

🔬Multiple myeloma patients in Australia could soon benefit from life-saving CAR-T therapy. Bernadette Savanoff was diagnosed with myeloma in late 2016. Unfortunately, after numerous treatments, she continues to live with 'dormant' myeloma. However, thanks to a recent MSAC recommendation for public funding, CAR-T therapy could now be within reach for Bernadette and many other patients. "Having CAR-T therapy recommended for funding and accessible to the myeloma community is absolutely amazing," Bernadette shared. However, she also expressed the frustration many feel about the lengthy approval process. Ensuring widespread patient access to these life-saving treatments requires a collective effort to make advanced therapies not only approvable, but accessible, and affordable too. Thank you Australian Broadcasting Corporation (ABC) for sharing Bernadette’s story ➡️ https://lnkd.in/edyb3kVZ #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🔬 Leveraging AI for scalable advanced therapy manufacturing At the recent Advanced Therapies Congress, Dr. Ioannis Papantoniou from KU Leuven shared the importance of integrated automation and well-controlled processes when leveraging data and AI. By incorporating smart bioreactors and multiplex sensors the industry can better measure critical quality attributes, enabling AI to predict complex cell behaviors and optimize manufacturing processes at scale. We've designed the IRO® platform with scalability and efficiency in mind, by automating labor-intensive processes to accelerate product development. Our digital platform empowers teams with data-led insights into manufacturing processes, giving flexibility and reliability at every stage of development. Learn how IRO® can help support your team ➡️ https://oribiotech.com/iro Read more: https://lnkd.in/eyYQRydN #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact/

🔬 A new biodegradable scaffold material could increase the efficacy of CAR-T therapy. Researchers at Harvard John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute at Harvard University have developed a biodegradable scaffold material which, when injected locally under the skin, can restimulate CAR-T cells after their administration. When tested in mice, this approach significantly curbed tumor growth and prolonged survival by increasing CAR-T cell numbers and their tumor-killing potential. Although this process is still in its early stages, it holds promise for translating to human treatments. The strategy could help improve CAR-T therapies in patients that do not initially respond well to treatment, making therapies accessible to more patients. Read more: https://lnkd.in/esC8iB6J #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

⚙️ Automation and scalability should be the minimum standard of CGT manufacturing Anshul Mangal, President at Project Farma (PF) joined Jason C. Foster on the Ori Spotlight Podcast, to speak about the integral need to rethink the development and delivery of cell and gene therapies. By integrating automation and scaleable processes, we can address key barriers in CGT manufacturing – enhancing efficiency and reducing manufacturing costs. By thinking about manufacturing early in development, the industry can ensure that these life-changing therapies can be produced at scale, meeting patient demand without compromising quality. Listen to the full discussion: 🎧Spotify: https://lnkd.in/efD6iM79 📺Youtube: https://lnkd.in/eWtHtexx #ManufacturingBrighterFutures #AutomateBetterBiology #AccelerateProductDevelopment #PatientAccess #Biotechnology

📣 Join us at the Four Seasons Hotel Dalton, Boston to experience IRO® - the New Standard of CGT Manufacturing 📅 September 17th, 17:00 ET 💬 During the evening, you can expect new real-world data from our IRO platform from Jason C. Foster, Ori Biotech CEO, and Matthew Hewitt, Vice President, CTO Manufacturing at Charles River Laboratories, and have the chance to experience IRO first-hand – with in-person demos showcasing how IRO can help accelerate product development and scale your impact. Definitely not one to miss! Secure your place today ➡️ https://lnkd.in/ep6p_DZ3 #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

In the summer of 2023, 15-year-old Uresa became the first child to receive CAR-T cell therapy for systemic lupus erythematosus (SLE). Uresa was diagnosed with SLE in late 2022, and despite various treatments, her condition rapidly deteriorated. Out of options, Dr. Tobias Krickau from Universitätsklinikum Erlangen suggested CAR-T cell therapy. After overcoming numerous hurdles, the treatment was finally administered and approved for use under compassionate use regulations in Germany. By July, Uresa’s kidney function was restored, and she returned home to resume her normal life. “Her kidney and lupus values improved from the third week after the treatment, “ says Dr. Krickau. “We had never achieved that with any medication previously.” In Uresa's case, she was approved for off-label use due to her age. As more and more advanced therapies are studied, we need to ensure they are both approvable and accessible so we can continue to transform the lives of everyone who could benefit – including children like Uresa. Thank you Technology Networks for sharing Uresa’s inspiring journey. ➡️ https://lnkd.in/eb2qWnjG #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Scientists at St. Jude Children's Research Hospital - ALSAC have identified 156 potential CAR-T cell therapy targets in brain and solid tumors – providing new possible targets for cancer treatment. The comprehensive analysis included 1,532 pediatric tumor samples and 7,460 normal tissue samples, and revealed cancer-specific genes that can be targeted without harming healthy cells. Amongst the potential targets, researchers have validated their top candidate, COL11A1, through in vivo testing. As the momentum of scientific development into CAR-T therapy grows, building scalable manufacturing solutions is critical to enable widespread patient access and meet the growing demand for advanced therapies. Read more: https://lnkd.in/dY8TkevV #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🔬Outpatient CAR-T cell therapy could offer a promising, accessible care pathway for patients New findings presented by the Mayo Clinic at the European Hematology Association (EHA) 2024 meeting demonstrate that administering CAR-T cell therapy in an outpatient setting can be both “safe and feasible” for patients with relapsed/refractory non-Hodgkin lymphoma. The 155-patient retrospective study compared outpatient delivery of axi-cel and brexu-cel, demonstrating successful implementation of early management strategies, and resulting in significantly improved outcomes such as less time spent in the hospital and fewer ICU visits. By embracing innovative biomanufacturing solutions and alternative care pathways, we can help improve the accessibility of these life-changing therapies while maintaining treatment safety and effectiveness. Read more: https://lnkd.in/eUekEUTv #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🧬 Bridging the gap between R&D and process development will help accelerate product development In our latest Ori Spotlight podcast episode, Jason C. Foster welcomed Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss how equipping researchers with advanced manufacturing technology early on in the development process will accelerate the journey to GMP. Implementing continual methodologies and equipment from research through GMP production can significantly streamline workflows, enhance efficiency, and speed up the journey from lab to patient. To overcome manufacturing hurdles and maximize the reach of advanced therapies, biopharma should be thinking early on about integrated approaches that span the entire development pipeline. This comprehensive strategy is essential for scaling impact, making these life-changing treatments more accessible and affordable for patients globally. 🎧 Listen on Spotify: https://lnkd.in/dmSEXjPp 📺 Watch on Youtube: https://lnkd.in/dcsYjjCZ #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact